| Year |
Citation |
Score |
| 2024 |
Cavanaugh D, Urbanucci A, Mohamed NE, Tewari AK, Figueiro M, Kyprianou N. Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS). The Prostate. PMID 38193363 DOI: 10.1002/pros.24656 |
0.302 |
|
| 2023 |
Wang J, Ben-David R, Mehrazin R, Yang W, Tewari AK, Kyprianou N. Novel signatures of prostate cancer progression and therapeutic resistance. Expert Opinion On Therapeutic Targets. PMID 38108262 DOI: 10.1080/14728222.2023.2293757 |
0.486 |
|
| 2023 |
Gupta KR, Kyprianou N. Microbiota and the landscape of the prostate tumor microenvironment. American Journal of Clinical and Experimental Urology. 11: 352-360. PMID 37941651 |
0.562 |
|
| 2023 |
Chen TY, Mihalopoulos M, Zuluaga L, Rich J, Ganta T, Mehrazin R, Tsao CK, Tewari A, Gonzalez-Kozlova E, Badani K, Dogra N, Kyprianou N. Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer. International Journal of Molecular Sciences. 24. PMID 37834162 DOI: 10.3390/ijms241914713 |
0.465 |
|
| 2023 |
Treacy PJ, Falagario UG, Magniez F, Ratnani P, Wajswol E, Martini A, Jambor I, Wiklund P, Bentellis I, Barthe F, Kyprianou N, Durand M, Steffens D, Karunaratne S, Leslie S, et al. Decipher Score predicts prostate specific antigen persistence after prostatectomy. Minerva Urology and Nephrology. 75: 583-590. PMID 37728494 DOI: 10.23736/S2724-6051.23.05395-8 |
0.338 |
|
| 2023 |
Treacy PJ, Martini A, Falagario UG, Ratnani P, Wajswol E, Beksac AT, Wiklund P, Nair S, Kyprianou N, Durand M, Tewari AK. Association between Expression of Connective Tissue Genes and Prostate Cancer Growth and Progression. International Journal of Molecular Sciences. 24. PMID 37108678 DOI: 10.3390/ijms24087520 |
0.331 |
|
| 2023 |
Nepali PR, Kyprianou N. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment. Frontiers in Endocrinology. 14: 1160267. PMID 37091854 DOI: 10.3389/fendo.2023.1160267 |
0.54 |
|
| 2023 |
Chakraborty G, Gupta K, Kyprianou N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nature Communications. 14: 567. PMID 36732329 DOI: 10.1038/s41467-023-36253-1 |
0.529 |
|
| 2022 |
Falagario UG, Chakravarty D, Martini A, Shahait M, El-Fahmawi A, Jambor I, Lantz A, Grannas D, Ratnani P, Parekh S, Lundon D, Haines K, Cormio L, Carrieri G, Kyprianou N, et al. When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic level. World Journal of Urology. PMID 36484816 DOI: 10.1007/s00345-022-04240-8 |
0.35 |
|
| 2022 |
Dasari SS, Archer M, Mohamed NE, Tewari AK, Figueiro MG, Kyprianou N. Circadian Rhythm Disruption as a Contributor to Racial Disparities in Prostate Cancer. Cancers. 14. PMID 36291899 DOI: 10.3390/cancers14205116 |
0.45 |
|
| 2022 |
Crowley F, Mihalopoulos M, Gaglani S, Tewari AK, Tsao CK, Djordjevic M, Kyprianou N, Purohit RS, Lundon DJ. Prostate cancer in transgender women: considerations for screening, diagnosis and management. British Journal of Cancer. PMID 36261584 DOI: 10.1038/s41416-022-01989-y |
0.477 |
|
| 2022 |
Sandhu HS, Portman KL, Zhou X, Zhao J, Rialdi A, Sfakianos JP, Guccione E, Kyprianou N, Zhang B, Mulholland DJ. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy. Cell Reports. 40: 111123. PMID 35905714 DOI: 10.1016/j.celrep.2022.111123 |
0.493 |
|
| 2022 |
Gaglani S, Purohit RS, Tewari AK, Kyprianou N, Lundon DJ. Embryologic and hormonal contributors to prostate cancer in transgender women. American Journal of Clinical and Experimental Urology. 10: 63-72. PMID 35528466 |
0.426 |
|
| 2022 |
Ratnani P, Dovey Z, Parekh S, Sobotka S, Shukla D, Davis A, Roshandel R, Wagaskar V, Jambor I, Lundon DJ, Wiklund P, Kyprianou N, Menon M, Tewari A. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology. The Prostate. PMID 35437769 DOI: 10.1002/pros.24344 |
0.378 |
|
| 2022 |
Kaur P, Mohamed NE, Archer M, Figueiro MG, Kyprianou N. Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. Frontiers in Oncology. 12: 759153. PMID 35356228 DOI: 10.3389/fonc.2022.759153 |
0.311 |
|
| 2022 |
Yan Y, Zhou B, Qian C, Vasquez A, Kamra M, Chatterjee A, Lee YJ, Yuan X, Ellis L, Di Vizio D, Posadas EM, Kyprianou N, Knudsen BS, Shah K, Murali R, et al. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nature Communications. 13: 669. PMID 35115556 DOI: 10.1038/s41467-022-28340-6 |
0.359 |
|
| 2021 |
Pavlova IP, Nair SS, Lundon D, Sobotka S, Roshandel R, Treacy PJ, Ratnani P, Brody R, Epstein JI, Ayala GE, Kyprianou N, Tewari AK. Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients. Journal of Personalized Medicine. 11. PMID 34834413 DOI: 10.3390/jpm11111061 |
0.429 |
|
| 2021 |
Kyprianou N, Lucien F. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer. International Journal of Molecular Sciences. 22. PMID 34769075 DOI: 10.3390/ijms222111645 |
0.503 |
|
| 2021 |
Gaglani S, Gonzalez-Kozlova E, Lundon DJ, Tewari AK, Dogra N, Kyprianou N. Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer. International Journal of Molecular Sciences. 22. PMID 34576294 DOI: 10.3390/ijms221810131 |
0.482 |
|
| 2021 |
Altschuler J, Stockert JA, Kyprianou N. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. International Journal of Molecular Sciences. 22. PMID 33672595 DOI: 10.3390/ijms22042100 |
0.502 |
|
| 2021 |
Archer M, Kyprianou N. Homeless Cells Escape Death and Deliver Lethal Cancer. Endocrinology. 162. PMID 33550388 DOI: 10.1210/endocr/bqab027 |
0.357 |
|
| 2020 |
Livas L, Hasani S, Kyprianou N. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1296: 183-198. PMID 34185293 DOI: 10.1007/978-3-030-59038-3_11 |
0.575 |
|
| 2020 |
Dovey Z, Mohamed N, Gharib Y, Ratnani P, Hammouda N, Nair SS, Chakravarty D, Sobotka S, Lantz A, Wiklund P, Kyprianou N, Tewari A. Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. European Urology Open Science. 20: 1-11. PMID 34173542 DOI: 10.1016/j.euros.2020.05.005 |
0.358 |
|
| 2020 |
Archer M, Dogra N, Kyprianou N. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. Cancers. 12. PMID 33076397 DOI: 10.3390/cancers12102984 |
0.548 |
|
| 2020 |
Wang YA, Sfakianos J, Tewari AK, Cordon-Cardo C, Kyprianou N. Molecular tracing of prostate cancer lethality. Oncogene. PMID 33046797 DOI: 10.1038/s41388-020-01496-5 |
0.504 |
|
| 2020 |
Kyprianou N. Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis. European Urology. PMID 32943261 DOI: 10.1016/j.eururo.2020.08.017 |
0.453 |
|
| 2020 |
Mihalopoulos M, Dovey Z, Archer M, Korn TG, Okhawere KE, Nkemdirim W, Funchess H, Rambhia A, Mohamed N, Kaplan SA, Mehrazin R, Lundon D, Tsao CK, Badani KK, Kyprianou N. Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers. 12. PMID 32872127 DOI: 10.3390/cancers12092442 |
0.332 |
|
| 2020 |
Stockert JA, Weil R, Yadav KK, Kyprianou N, Tewari AK. Pseudouridine as a novel biomarker in prostate cancer. Urologic Oncology. PMID 32712138 DOI: 10.1016/j.urolonc.2020.06.026 |
0.404 |
|
| 2020 |
Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V, Mohamed N, Lundon D, Dovey Z, Kyprianou N, Tewari AK. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Communications Biology. 3: 374. PMID 32641750 DOI: 10.1038/s42003-020-1088-9 |
0.439 |
|
| 2020 |
Begemann D, Wang Y, Yang W, Kyprianou N. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. The Prostate. PMID 32542812 DOI: 10.1002/pros.24015 |
0.547 |
|
| 2020 |
Han R, Hensley PJ, Li J, Zhang Y, Stark TW, Heller A, Qian H, Shi J, Liu Z, Huang JA, Jin T, Wei X, Zhou BP, Wu Y, Kyprianou N, et al. Integrin-associated CD151 is a suppressor of prostate cancer progression. American Journal of Translational Research. 12: 1428-1442. PMID 32355552 |
0.374 |
|
| 2020 |
Falagario UG, Jambor I, Ratnani P, Martini A, Treacy PJ, Wajswol E, Lantz A, Papastefanou G, Weil R, Phillip D, Lewis S, Haines K, Cormio L, Carrieri G, Kyprianou N, et al. Performance of prostate multiparametric MRI for prediction of prostate cancer extraprostatic extension according to NCCN risk categories: implication for surgical planning. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology. PMID 32182231 DOI: 10.23736/S0393-2249.20.03688-7 |
0.394 |
|
| 2020 |
Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, ... Kyprianou N, et al. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Scientific Reports. 10: 1292. PMID 31992742 DOI: 10.1038/S41598-020-58136-X |
0.434 |
|
| 2020 |
Lantz* A, Falagario UG, Jambor I, Martini A, Ratnani P, Treacy P, Phillip D, Lewis S, Carrieri G, Kyprianou N, Tewari AK. MP09-09 USING BIOMARKERS IN PATIENTS WITH A POSITIVE MPMRI. 4KSCORE PREDICTS PRESENCE OF CANCER OUTSIDE THE INDEX LESION The Journal of Urology. 203: e119. DOI: 10.1097/Ju.0000000000000829.09 |
0.464 |
|
| 2020 |
Dovey Z, Mohamed N, Gharib Y, Ratnani P, Hammouda N, Nair SS, Chakravarty D, Sobotka S, Lantz A, Wiklund P, Kyprianou N, Tewari A. Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists European Urology Open Science. 20: 1-11. DOI: 10.1016/j.euros.2020.05.005 |
0.457 |
|
| 2019 |
Wade CA, Kyprianou N. Adipose tissue: enabler of prostate cancer aggressive behavior. Translational Andrology and Urology. 8: S242-S245. PMID 31392134 DOI: 10.21037/Tau.2019.01.07 |
0.597 |
|
| 2019 |
Hensley PJ, Kyprianou N, Purdom MS, He D, DiCarlo V, Wang C, James AC. Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urologic Oncology. PMID 31326313 DOI: 10.1016/J.Urolonc.2019.06.020 |
0.306 |
|
| 2019 |
Hensley PJ, Cao Z, Pu H, Dicken H, He D, Zhou Z, Wang C, Koochekpour S, Kyprianou N. Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer. American Journal of Clinical and Experimental Urology. 7: 188-202. PMID 31317059 |
0.544 |
|
| 2019 |
Wade CA, Goodwin J, Preston D, Kyprianou N. Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention. American Journal of Clinical and Experimental Urology. 7: 46-60. PMID 30906804 |
0.54 |
|
| 2019 |
Dicken H, Hensley PJ, Kyprianou N. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. Asian Journal of Urology. 6: 82-90. PMID 30775251 DOI: 10.1016/J.Ajur.2018.11.001 |
0.584 |
|
| 2019 |
Kyprianou N. Induction of apoptosis by alpha1-adrenoceptor antagonists in benign prostatic hyperplasia and prostate cancer. Prostate Cancer and Prostatic Diseases. 3: S24-S25. PMID 12497134 DOI: 10.1038/Sj.Pcan.4500450 |
0.623 |
|
| 2019 |
Kyprianou N. Activation of TGF-beta signalling in human prostate cancer cells suppresses tumorigenicity via deregulation of cell cycle progression and induction of caspase-1 mediated apoptosis: significance in prostate tumorigenesis. Prostate Cancer and Prostatic Diseases. 2: S18. PMID 12496798 DOI: 10.1038/Sj.Pcan.4500344 |
0.643 |
|
| 2018 |
Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ, Kyprianou N. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. The Prostate. PMID 30155899 DOI: 10.1002/Pros.23708 |
0.59 |
|
| 2018 |
Chaiswing L, Weiss HL, Jayswal RD, Clair DKS, Kyprianou N. Profiles of Radioresistance Mechanisms in Prostate Cancer. Critical Reviews in Oncogenesis. 23: 39-67. PMID 29953367 DOI: 10.1615/Critrevoncog.2018025946 |
0.519 |
|
| 2018 |
Yang W, Freeman MR, Kyprianou N. Personalization of prostate cancer therapy through phosphoproteomics. Nature Reviews. Urology. PMID 29752463 DOI: 10.1038/S41585-018-0014-0 |
0.48 |
|
| 2018 |
Wade CA, Kyprianou N. Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences. 19. PMID 29562686 DOI: 10.3390/Ijms19030904 |
0.596 |
|
| 2018 |
Begemann D, Anastos H, Kyprianou N. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 29345000 DOI: 10.1111/Iju.13505 |
0.632 |
|
| 2018 |
Paller CJ, Pu H, Begemann D, Nakazawa M, Kyprianou N. Overcoming resistance to antiandrogens with a TGF-β RI inhibitor in preclinical mouse model of PCa. Journal of Clinical Oncology. 36: 288-288. DOI: 10.1200/Jco.2018.36.6_Suppl.288 |
0.428 |
|
| 2018 |
Hensley P, Cao Z, Koochekpoor S, Kyprianou N. PD14-02 OVERCOMING RESISTANCE TO ANTIANDROGENS VIA TARGETING IGBP3 IN PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.788 |
0.501 |
|
| 2017 |
Cao Z, Koochekpour S, Strup SE, Kyprianou N. Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. Oncotarget. 8: 78507-78519. PMID 29108245 DOI: 10.18632/Oncotarget.19659 |
0.641 |
|
| 2017 |
Stark TW, Hensley PJ, Spear A, Pu H, Strup SS, Kyprianou N. Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance. The Prostate. 77: 1583-1591. PMID 29063620 DOI: 10.1002/Pros.23435 |
0.606 |
|
| 2017 |
Cao Z, Koochekpour S, Strup SE, Kyprianou N. Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. Oncotarget. PMID 28775239 DOI: 10.18632/oncotarget.19659 |
0.573 |
|
| 2017 |
Pu H, Begemann D, Kyprianou N. Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis. Endocrinology. PMID 28324007 DOI: 10.1210/En.2017-00086 |
0.563 |
|
| 2017 |
Nakazawa M, Paller C, Kyprianou N. Mechanisms of Therapeutic Resistance in Prostate Cancer. Current Oncology Reports. 19: 13. PMID 28229393 DOI: 10.1007/S11912-017-0568-7 |
0.557 |
|
| 2017 |
Cao Z, Koochekpour S, Strup SE, Kyprianou N. Abstract 2122: Pharmacologic interconversion of EMT to MET for prostate cancer Cancer Research. 77: 2122-2122. DOI: 10.1158/1538-7445.Am2017-2122 |
0.659 |
|
| 2017 |
Cao Z, Koochekpour S, Strup S, Kyprianou N. PD33-03 PHARMACOLOGIC TARGETING OF TGF-β MEDIATED EMT IN PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3317 |
0.493 |
|
| 2016 |
Cao Z, Livas T, Kyprianou N. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. Critical Reviews in Oncogenesis. 21: 155-168. PMID 27915969 DOI: 10.1615/Critrevoncog.2016016955 |
0.471 |
|
| 2016 |
Kyprianou N. Prostate cancer: Kinases and CHIPS sign-off personalization of therapy. Nature Reviews. Urology. PMID 27725640 DOI: 10.1038/Nrurol.2016.194 |
0.516 |
|
| 2016 |
Shourideh M, Azabdaftari G, Attwood K, DePriest A, Wadosky KM, Gillard BM, Karasik E, Heemers H, Kyprianou N, Gelman IH, Corey E, Vessella RL, Mohler JL, Koochekpour S. GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27458247 DOI: 10.1158/1078-0432.Ccr-16-0137 |
0.597 |
|
| 2016 |
Hensley PJ, Zetter D, Horbinski CM, Strup SE, Kyprianou N. Association of Epithelial-Mesenchymal-Transition and Nuclear Cofilin with Advanced Urothelial Cancer. Human Pathology. PMID 27402302 DOI: 10.1016/J.Humpath.2016.06.020 |
0.467 |
|
| 2016 |
Nakazawa M, Kyprianou N. Epithelial-Mesenchymal-Transition Regulators in Prostate Cancer: Androgens and Beyond. The Journal of Steroid Biochemistry and Molecular Biology. PMID 27189666 DOI: 10.1016/J.Jsbmb.2016.05.007 |
0.593 |
|
| 2015 |
Cao Z, Kyprianou N. Mechanisms navigating the TGF-β pathway in prostate cancer. Asian Journal of Urology. 2: 11-18. PMID 29051866 DOI: 10.1016/J.Ajur.2015.04.011 |
0.519 |
|
| 2015 |
Stark T, Livas L, Kyprianou N. Inflammation in prostate cancer progression and therapeutic targeting. Translational Andrology and Urology. 4: 455-63. PMID 26816843 DOI: 10.3978/J.Issn.2223-4683.2015.04.12 |
0.58 |
|
| 2015 |
Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N. Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Research. PMID 26645563 DOI: 10.1158/0008-5472.Can-15-2078 |
0.606 |
|
| 2015 |
Broster SA, Kyprianou N. Epithelial-mesenchymal transition in prostatic disease. Future Oncology (London, England). 11: 3197-206. PMID 26551285 DOI: 10.2217/Fon.15.253 |
0.563 |
|
| 2015 |
Zhou P, Erfani S, Liu Z, Jia C, Chen Y, Xu B, Deng X, Alfaro JE, Chen L, Napier D, Lu M, Huang JA, Liu C, Thibault O, Segal R, ... ... Kyprianou N, et al. CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget. PMID 26377974 DOI: 10.18632/Oncotarget.4896 |
0.375 |
|
| 2015 |
Martin SK, Kyprianou N. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Advances in Cancer Research. 127: 123-58. PMID 26093899 DOI: 10.1016/Bs.Acr.2015.03.001 |
0.585 |
|
| 2015 |
Martin SK, Pu H, Horbinski C, Cao Z, Kyprianou N. Abstract 2567: Cabazitaxel chemotherapy targets mitotic kinesins resulting in multi-nucleation of prostate cancer cells: A novel mechanism of cross-resistance with antiandrogens in advanced CRPC Cancer Research. 75: 2567-2567. DOI: 10.1158/1538-7445.Am2015-2567 |
0.613 |
|
| 2015 |
Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, Damodaran C. Erratum: Diosgenin targets akt-mediated pro-survival signaling in human breast cancer cells (International Journal of Cancer (2009) 125:4 (961-967) DOI: 10.1002/ijc.24419) International Journal of Cancer. 136. DOI: 10.1002/Ijc.29179 |
0.423 |
|
| 2014 |
Miremami J, Kyprianou N. The promise of novel molecular markers in bladder cancer. International Journal of Molecular Sciences. 15: 23897-908. PMID 25535079 DOI: 10.3390/Ijms151223897 |
0.359 |
|
| 2014 |
Martin SK, Banuelos CA, Sadar MD, Kyprianou N. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Molecular Oncology. PMID 25432105 DOI: 10.1016/J.Molonc.2014.10.014 |
0.555 |
|
| 2014 |
Martin SK, Kamelgarn M, Kyprianou N. Cytoskeleton targeting value in prostate cancer treatment. American Journal of Clinical and Experimental Urology. 2: 15-26. PMID 25374905 |
0.56 |
|
| 2014 |
Kyprianou N. The fringe benefits of cloning cancer. Science Translational Medicine. 6: 254fs36. PMID 25232174 DOI: 10.1126/Scitranslmed.3010174 |
0.499 |
|
| 2014 |
Lacy JM, Kyprianou N. A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review). Oncology Letters. 8: 1391-1396. PMID 25202340 DOI: 10.3892/Ol.2014.2388 |
0.563 |
|
| 2014 |
Pu H, Horbinski C, Hensley PJ, Matuszak EA, Atkinson T, Kyprianou N. PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis. 35: 2592-601. PMID 25173886 DOI: 10.1093/Carcin/Bgu183 |
0.628 |
|
| 2014 |
Liu Y, Gilbert MR, Kyprianou N, Rangnekar VM, Horbinski C. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathologica. 128: 723-32. PMID 25135281 DOI: 10.1007/S00401-014-1334-7 |
0.533 |
|
| 2014 |
Kahn B, Collazo J, Kyprianou N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. International Journal of Biological Sciences. 10: 588-95. PMID 24948871 DOI: 10.7150/Ijbs.8671 |
0.656 |
|
| 2014 |
Collazo J, Zhu B, Larkin S, Martin SK, Pu H, Horbinski C, Koochekpour S, Kyprianou N. Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Research. 74: 2362-73. PMID 24509905 DOI: 10.1158/0008-5472.Can-13-3058 |
0.609 |
|
| 2014 |
Hensley PJ, Desiniotis A, Wang C, Stromberg A, Chen CS, Kyprianou N. Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells. Plos One. 9: e86238. PMID 24497940 DOI: 10.1371/Journal.Pone.0086238 |
0.626 |
|
| 2014 |
Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N, Horbinski C. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathologica. 127: 221-33. PMID 24150401 DOI: 10.1007/S00401-013-1194-6 |
0.351 |
|
| 2014 |
Horbinski C, Liu Y, Gilbert MR, Kyprianou N. MUTANT IDH1 SUPPRESSES APOPTOSIS REGULATOR PAR-4 IN GLIOMAS Neuro-Oncology. 16: iii6-iii6. DOI: 10.1093/Neuonc/Nou206.21 |
0.435 |
|
| 2014 |
Cao Z, Kyprianou N. WITHDRAWN: Mechanisms navigating the TGF-β pathway in prostate cancer Asian Journal of Urology. DOI: 10.1016/J.Ajur.2014.09.005 |
0.548 |
|
| 2013 |
Hendrix LN, Hamilton DA, Kyprianou N. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition. Expert Review of Endocrinology & Metabolism. 8: 403-416. PMID 30736155 DOI: 10.1586/17446651.2013.811914 |
0.608 |
|
| 2013 |
Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Translational Andrology and Urology. 2: 202-211. PMID 25346895 DOI: 10.3978/J.Issn.2223-4683.2013.09.04 |
0.562 |
|
| 2013 |
Bilbro J, Mart M, Kyprianou N. Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Research. 33: 4695-700. PMID 24222103 |
0.471 |
|
| 2013 |
Fiandalo MV, Kyprianou N. p27 Stands-up-to-cancer: UPS nuclear service stops. Endocrinology. 154: 3970-3. PMID 24141996 DOI: 10.1210/En.2013-1873 |
0.76 |
|
| 2013 |
Larkin S, Kyprianou N. Molecular signatures in urologic tumors. International Journal of Molecular Sciences. 14: 18421-36. PMID 24018887 DOI: 10.3390/Ijms140918421 |
0.441 |
|
| 2013 |
Hensley P, Mishra M, Kyprianou N. Targeting caspases in cancer therapeutics. Biological Chemistry. 394: 831-43. PMID 23509217 DOI: 10.1515/Hsz-2013-0128 |
0.48 |
|
| 2013 |
Fiandalo MV, Schwarze SR, Kyprianou N. Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis : An International Journal On Programmed Cell Death. 18: 766-76. PMID 23456622 DOI: 10.1007/S10495-013-0821-Y |
0.807 |
|
| 2013 |
Matuszak EA, Kyprianou N. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. Bju International. 111: 6-7. PMID 23107294 DOI: 10.1111/J.1464-410X.2012.11566.X |
0.513 |
|
| 2013 |
Hendrix LN, Hamilton DA, Kyprianou N. Emerging therapeutics targeting castration-resistant prostate cancer: The AR-mageddon of tumor epithelial-mesenchymal transition Expert Review of Endocrinology and Metabolism. 8: 403-416. DOI: 10.1586/17446651.2013.811914 |
0.483 |
|
| 2012 |
Fiandalo MV, Kyprianou N. Caspase control: protagonists of cancer cell apoptosis. Experimental Oncology. 34: 165-75. PMID 23070001 |
0.802 |
|
| 2012 |
Martin SK, Vaughan TB, Atkinson T, Zhu H, Kyprianou N. Emerging biomarkers of prostate cancer (Review). Oncology Reports. 28: 409-17. PMID 22641253 DOI: 10.3892/Or.2012.1832 |
0.629 |
|
| 2012 |
Hensley PJ, Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. Journal of Andrology. 33: 133-44. PMID 21680808 DOI: 10.2164/Jandrol.111.013987 |
0.591 |
|
| 2012 |
Zhu H, Zhao J, Zhu B, Collazo J, Gal J, Shi P, Liu L, Ström AL, Lu X, McCann RO, Toborek M, Kyprianou N. EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. The Prostate. 72: 72-81. PMID 21563192 DOI: 10.1002/Pros.21408 |
0.604 |
|
| 2012 |
Fiandalo M, Schwarze S, Kyprianou N. Abstract 4969: Impact of proteasome inhibition of caspase-8 regulation in cancer Cancer Research. 72: 4969-4969. DOI: 10.1158/1538-7445.Am2012-4969 |
0.792 |
|
| 2012 |
Martin SK, Fiandalo MV, Kyprianou N. Androgen receptor signaling interactions control epithelial-mesenchymal transition (EMT) in prostate cancer progression Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications. 227-255. DOI: 10.1007/978-1-4614-6182-1_15 |
0.793 |
|
| 2011 |
Matuszak EA, Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Review of Endocrinology & Metabolism. 6: 469-482. PMID 23667383 DOI: 10.1586/Eem.11.32 |
0.618 |
|
| 2011 |
Desiniotis A, Kyprianou N. Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opinion On Therapeutic Targets. 15: 1405-18. PMID 22148952 DOI: 10.1517/14728222.2011.641534 |
0.448 |
|
| 2011 |
Desiniotis A, Kyprianou N. Significance of talin in cancer progression and metastasis. International Review of Cell and Molecular Biology. 289: 117-47. PMID 21749900 DOI: 10.1016/B978-0-12-386039-2.00004-3 |
0.576 |
|
| 2011 |
Tang X, Tang X, Gal J, Kyprianou N, Zhu H, Tang G. Detection of microRNAs in prostate cancer cells by microRNA array. Methods in Molecular Biology (Clifton, N.J.). 732: 69-88. PMID 21431706 DOI: 10.1007/978-1-61779-083-6_6 |
0.423 |
|
| 2011 |
Sakamoto S, Schwarze S, Kyprianou N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. European Urology. 59: 734-44. PMID 21269758 DOI: 10.1016/J.Eururo.2010.12.038 |
0.381 |
|
| 2011 |
Martin SK, Kyprianou N. Gene fusions find an ERG-way to tumor inflammation. Cancer Biology & Therapy. 11: 418-20. PMID 21248480 DOI: 10.4161/Cbt.11.4.14499 |
0.549 |
|
| 2010 |
Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research. 70: 7992-8002. PMID 20807808 DOI: 10.1158/0008-5472.Can-10-0585 |
0.72 |
|
| 2010 |
Horbinski C, Mojesky C, Kyprianou N. Live free or die: tales of homeless (cells) in cancer. The American Journal of Pathology. 177: 1044-52. PMID 20639456 DOI: 10.2353/Ajpath.2010.091270 |
0.454 |
|
| 2010 |
Sakamoto S, McCann RO, Dhir R, Kyprianou N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Research. 70: 1885-95. PMID 20160039 DOI: 10.1158/0008-5472.Can-09-2833 |
0.643 |
|
| 2010 |
Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Molecular Aspects of Medicine. 31: 205-14. PMID 20153362 DOI: 10.1016/J.Mam.2010.02.001 |
0.585 |
|
| 2010 |
Kyprianou N. ASK-ing EMT not to spread cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 2731-2. PMID 20145111 DOI: 10.1073/Pnas.0914721107 |
0.346 |
|
| 2010 |
Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 769-77. PMID 19901020 DOI: 10.1096/Fj.09-136994 |
0.72 |
|
| 2010 |
Zhu B, Zhai J, Zhu H, Kyprianou N. Prohibitin regulates TGF-beta induced apoptosis as a downstream effector of Smad-dependent and -independent signaling. The Prostate. 70: 17-26. PMID 19725029 DOI: 10.1002/Pros.21033 |
0.461 |
|
| 2010 |
Strup S, Quillin R, Pu H, Houtz J, Jones E, Kyprianou N, Esser K. 1440 EFFECT OF EXERCISE ON PROSTATE CANCER IN THE TRANSGENIC ADENOCARCINOMA OF THE MOUSE PROSTATE (TRAMP) MODEL Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1133 |
0.559 |
|
| 2010 |
Kyprianou N. PL3-2 TGF-β and androgen signaling cross-talk regulates apoptosis and epithelial-mesenchymal-transition (EMT) in prostate cancer Cytokine. 52: 68. DOI: 10.1016/J.Cyto.2010.07.288 |
0.564 |
|
| 2009 |
Kyprianou N, Vaughan TB, Michel MC. Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn-Schmiedeberg's Archives of Pharmacology. 380: 473-7. PMID 19904527 DOI: 10.1007/S00210-009-0462-4 |
0.512 |
|
| 2009 |
Pu H, Collazo J, Jones E, Gayheart D, Sakamoto S, Vogt A, Mitchell B, Kyprianou N. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Research. 69: 7366-74. PMID 19738062 DOI: 10.1158/0008-5472.Can-09-0758 |
0.582 |
|
| 2009 |
Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, Damodaran C. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. International Journal of Cancer. 125: 961-7. PMID 19384950 DOI: 10.1002/Ijc.24419 |
0.455 |
|
| 2009 |
Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opinion On Therapeutic Targets. 13: 227-34. PMID 19236240 DOI: 10.1517/14728220802705696 |
0.572 |
|
| 2009 |
Kumar R, Srinivasan S, Koduru S, Pahari P, Rohr J, Kyprianou N, Damodaran C. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prevention Research (Philadelphia, Pa.). 2: 234-43. PMID 19223576 DOI: 10.1158/1940-6207.Capr-08-0129 |
0.654 |
|
| 2009 |
Sakamoto S, McCann RO, Kyprianou N. Talin1 Promotes Prostate Cancer Invasion and Metastasis via AKT Signaling and Anoikis Resistance Nature Precedings. DOI: 10.1038/Npre.2009.3059.1 |
0.648 |
|
| 2008 |
Martin FM, Harris AM, Rowland RG, Conner W, Lane M, Durbin E, Baron AT, Kyprianou N. Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Therapy & Molecular Biology. 12: 253-258. PMID 20717483 |
0.362 |
|
| 2008 |
McKenzie S, Sakamoto S, Kyprianou N. Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene. 27: 7171-9. PMID 18931702 DOI: 10.1038/Onc.2008.321 |
0.668 |
|
| 2008 |
Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocrine-Related Cancer. 15: 841-9. PMID 18667687 DOI: 10.1677/Erc-08-0084 |
0.697 |
|
| 2008 |
Schwarze SR, Lin EW, Christian PA, Gayheart DT, Kyprianou N. Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. The Prostate. 68: 1615-23. PMID 18663729 DOI: 10.1002/Pros.20828 |
0.564 |
|
| 2008 |
Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. The Prostate. 68: 287-95. PMID 18163430 DOI: 10.1002/Pros.20698 |
0.642 |
|
| 2008 |
Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. Journal of Cellular Biochemistry. 103: 691-708. PMID 17668426 DOI: 10.1002/Jcb.21442 |
0.486 |
|
| 2008 |
Kyprianou N. TGF-β signaling dictates therapeutic targeting in prostate cancer Therapy. 5: 7-11. DOI: 10.2217/14750708.5.1.7 |
0.637 |
|
| 2008 |
Sakamoto S, McCann R, Kyprianou N. TALIN AS A NOVEL MEDIATOR OF PROSTATE CANCER CELL MIGRATION, INVASION AND METASTASIS Journal of Urology. 179: 459-460. DOI: 10.1016/S0022-5347(08)61349-X |
0.614 |
|
| 2007 |
Garrison JB, Shaw YJ, Chen CS, Kyprianou N. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Research. 67: 11344-52. PMID 18056461 DOI: 10.1158/0008-5472.Can-07-1662 |
0.81 |
|
| 2007 |
Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. The Journal of Urology. 178: 2176-80. PMID 17870114 DOI: 10.1016/J.Juro.2007.06.043 |
0.554 |
|
| 2007 |
Velez W, Kyprianou N. Emmprin is a Biomarker of Prostate Cancer Progression in TRAMP Mice The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A621 |
0.552 |
|
| 2007 |
Rybak B, Kyprianou N. Doxazosin‐derived DZ‐3 Compound Enhances Apoptotic Ability of Maspin‐sensitized Prostate Cancer Cells The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A247 |
0.609 |
|
| 2007 |
Harris AM, Rowland RG, Kimbler K, Conner W, Durbin E, Baron AT, Kyprianou N. 1094: Decreased Risk for Bladder Cancer in Men Treated with Quinazoline-A1-Adrenoceptor Antagonists Journal of Urology. 177: 361-361. DOI: 10.1016/S0022-5347(18)31308-9 |
0.36 |
|
| 2006 |
Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate. 66: 1768-78. PMID 16955399 DOI: 10.1002/Pros.20509 |
0.772 |
|
| 2006 |
Zhu B, Fukada K, Zhu H, Kyprianou N. Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Research. 66: 8640-7. PMID 16951178 DOI: 10.1158/0008-5472.Can-06-1443 |
0.448 |
|
| 2006 |
Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP. Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia (New York, N.Y.). 8: 523-33. PMID 16820098 DOI: 10.1593/Neo.05745 |
0.665 |
|
| 2006 |
Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC, Kyprianou N. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. The Prostate. 66: 1194-202. PMID 16652387 DOI: 10.1002/Pros.20444 |
0.618 |
|
| 2006 |
Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. British Journal of Pharmacology. 147: S144-52. PMID 16465179 DOI: 10.1038/Sj.Bjp.0706635 |
0.612 |
|
| 2006 |
Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Research. 66: 464-72. PMID 16397262 DOI: 10.1158/0008-5472.Can-05-2039 |
0.808 |
|
| 2006 |
McKenzie S, Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. Journal of Cellular Biochemistry. 97: 18-32. PMID 16216007 DOI: 10.1002/Jcb.20634 |
0.609 |
|
| 2006 |
Harris A, Wilson JM, Becker A, Warner B, Rowland RG, Connor W, Durbin E, Kim M, Baron A, Kyprianou N. 127: Effect of α1-Adrenoceptor Antagonists on Prostate Cancer Incidence: A Retrospective Analysis Journal of Urology. 175: 40-41. DOI: 10.1016/S0022-5347(18)32394-2 |
0.557 |
|
| 2005 |
Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Research. 65: 11230-5. PMID 16357123 DOI: 10.1158/0008-5472.Can-05-2763 |
0.659 |
|
| 2005 |
Lee YW, Hirani AA, Kyprianou N, Toborek M. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells Inflammation Research. 54: 380-389. PMID 16273337 DOI: 10.1007/S00011-005-1371-8 |
0.321 |
|
| 2005 |
Zhu B, Kyprianou N. Transforming growth factor beta and prostate cancer. Cancer Treatment and Research. 126: 157-73. PMID 16209066 DOI: 10.1007/0-387-24361-5_7 |
0.566 |
|
| 2005 |
Tahmatzopoulos A, Sheng S, Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene. 24: 5375-83. PMID 16007219 DOI: 10.1038/Sj.Onc.1208684 |
0.658 |
|
| 2005 |
Tahmatzopoulos A, Lagrange CA, Zeng L, Mitchell BL, Conner WT, Kyprianou N. Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology. 65: 1019-23. PMID 15882756 DOI: 10.1016/J.Urology.2004.12.015 |
0.603 |
|
| 2005 |
Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. Journal of Cellular Biochemistry. 94: 374-88. PMID 15526277 DOI: 10.1002/Jcb.20240 |
0.746 |
|
| 2005 |
Zeng L, Kyprianou N. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer and Prostatic Diseases. 8: 7-13. PMID 15477876 DOI: 10.1038/Sj.Pcan.4500757 |
0.638 |
|
| 2005 |
LaGrange CA, Tahmatzopoulos A, Li Z, Mitchell BL, Conner WT, Kyprianou N. 581: The Effect of Terazosin on Apoptosis and Tissue Vascularity in Transitional Cell Carcinoma of the Bladder Journal of Urology. 173: 159-159. DOI: 10.1016/S0022-5347(18)34821-3 |
0.332 |
|
| 2004 |
Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS. Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. Journal of Medicinal Chemistry. 47: 4453-62. PMID 15317457 DOI: 10.1021/Jm049752K |
0.787 |
|
| 2004 |
Hill B, Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. The Prostate. 61: 73-80. PMID 15287095 DOI: 10.1002/Pros.20088 |
0.652 |
|
| 2004 |
Winter RN, Rhee JG, Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Research. 24: 1377-86. PMID 15274298 |
0.516 |
|
| 2004 |
Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opinion On Pharmacotherapy. 5: 1279-85. PMID 15163273 DOI: 10.1517/14656566.5.6.1279 |
0.653 |
|
| 2004 |
Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Human Pathology. 35: 290-7. PMID 15017584 DOI: 10.1016/J.Humpath.2003.11.001 |
0.594 |
|
| 2004 |
Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? The Prostate. 59: 91-100. PMID 14991869 DOI: 10.1002/Pros.10357 |
0.643 |
|
| 2004 |
Garrison JB, Kyprianou N. Novel targeting of apoptosis pathways for prostate cancer therapy. Current Cancer Drug Targets. 4: 85-95. PMID 14965270 DOI: 10.2174/1568009043481623 |
0.837 |
|
| 2003 |
Partin JV, Anglin IE, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. British Journal of Cancer. 88: 1615-21. PMID 12771931 DOI: 10.1038/Sj.Bjc.6600961 |
0.571 |
|
| 2003 |
Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. The Journal of Urology. 169: 1520-5. PMID 12629407 DOI: 10.1097/01.Ju.0000033280.29453.72 |
0.611 |
|
| 2003 |
Keledjian K, Kyprianou N. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. The Journal of Urology. 169: 1150-6. PMID 12576871 DOI: 10.1097/01.Ju.0000042453.12079.77 |
0.552 |
|
| 2003 |
Anglin IE, Glassman DT, Kyprianou N. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer and Prostatic Diseases. 5: 88-95. PMID 12496995 DOI: 10.1038/Sj.Pcan.4500561 |
0.612 |
|
| 2003 |
Kyprianou N, Jacobs SC. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs. Current Urology Reports. 1: 89-96. PMID 12084321 DOI: 10.1007/S11934-000-0042-0 |
0.631 |
|
| 2002 |
Hill B, Kyprianou N. Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). Oncology Reports. 9: 1151-6. PMID 12375010 DOI: 10.3892/Or.9.6.1151 |
0.672 |
|
| 2002 |
Bruckheimer EM, Kyprianou N. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. The Prostate. 53: 133-42. PMID 12242728 DOI: 10.1002/Pros.10143 |
0.604 |
|
| 2002 |
Cuellar DC, Rhee J, Kyprianou N. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Research. 22: 1673-9. PMID 12168853 |
0.533 |
|
| 2002 |
Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Research. 62: 597-602. PMID 11809715 |
0.532 |
|
| 2001 |
Bruckheimer EM, Kyprianou N. Dihydrotestosterone Enhances Transforming Growth Factor-β-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells. Endocrinology. 142: 2419-2426. PMID 28201237 DOI: 10.1210/Endo.142.6.8218 |
0.451 |
|
| 2001 |
Gill JK, Wang L, Bretner M, Newman R, Kyprianou N, Hosmane RS. Potent in vitro anticancer activities of ring-expanded ("fat") nucleosides containing the imidazo[4,5-E][1,3]diazepine ring system Nucleosides, Nucleotides and Nucleic Acids. 20: 1043-1045. PMID 11562954 DOI: 10.1081/Ncn-100002487 |
0.439 |
|
| 2001 |
Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. The Prostate. 48: 71-8. PMID 11433417 DOI: 10.1002/Pros.1083 |
0.565 |
|
| 2001 |
Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. The Prostate. 46: 45-51. PMID 11170131 DOI: 10.1002/1097-0045(200101)46:1<45::Aid-Pros1007>3.0.Co;2-U |
0.582 |
|
| 2001 |
Cuellar DC, Kyprianou N. Future concepts in the medical therapy of benign prostatic hyperplasia. Current Opinion in Urology. 11: 27-33. PMID 11148743 DOI: 10.1097/00042307-200101000-00004 |
0.504 |
|
| 2001 |
Kyprianou N, Bruckheimer EM, Guo Y. Cell proliferation and apoptosis in prostate cancer: significance in disease progression and therapy. Histology and Histopathology. 15: 1211-23. PMID 11005246 DOI: 10.14670/Hh-15.1211 |
0.619 |
|
| 2001 |
SZOSTAK MJ, KAUR P, AMIN P, JACOBS SC, KYPRIANOU N. APOPTOSIS AND BCL-2 EXPRESSION IN PROSTATE CANCER: SIGNIFICANCE IN CLINICAL OUTCOME AFTER BRACHYTHERAPY Journal of Urology. 165: 2126-2130. DOI: 10.1016/S0022-5347(05)66306-9 |
0.615 |
|
| 2000 |
Kyprianou N, Chon J, Benning CM. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease The Prostate. Supplement. 9: 42-46. PMID 11056502 DOI: 10.1002/1097-0045(2000)45:9+<42::Aid-Pros9>3.0.Co;2-U |
0.602 |
|
| 2000 |
Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell and Tissue Research. 301: 153-62. PMID 10928288 DOI: 10.1007/S004410000196 |
0.646 |
|
| 2000 |
Szostak MJ, Kyprianou N. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncology Reports. 7: 699-706. PMID 10854529 DOI: 10.3892/or.7.4.699 |
0.562 |
|
| 2000 |
Guo Y, Sigman DB, Borkowski A, Kyprianou N. Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. The Prostate. 42: 130-6. PMID 10617870 DOI: 10.1002/(Sici)1097-0045(20000201)42:2<130::Aid-Pros7>3.0.Co;2-3 |
0.606 |
|
| 1999 |
Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. The American Journal of Pathology. 155: 1129-36. PMID 10514396 DOI: 10.1016/S0002-9440(10)65216-9 |
0.344 |
|
| 1999 |
Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N. α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia Journal of Urology. 161: 2002-2008. PMID 10332490 DOI: 10.1016/S0022-5347(05)68873-8 |
0.513 |
|
| 1999 |
Epstein JI, Partin AW, Simon I, Kyprianou N, Hess DL, Prins G, Marks LS, Dorey FJ, Macairan ML, Santos PBC. Prostate Tissue Effects Of Saw Palmetto Extract In Men With Symptomatic Bph The Journal of Urology. 362. DOI: 10.1097/00005392-199904020-00450 |
0.473 |
|
| 1999 |
Glassman DT, Borkowski A, Jacobs SC, Kyprianou N. EFFECT OF DOXAZOSIN MEDIATED ALPHA -1 BLOCKADE ON TGF-beta AND p27 EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA The Journal of Urology. 228. DOI: 10.1097/00005392-199904010-00915 |
0.466 |
|
| 1999 |
Glassman DT, Chon JK, Borkowski A, Isaacs JT, Jacobs SC, Kyprianou N. Effect Of Finasteride And Terazosin On Apoptotic And Proliferative Indices In Benign Prostatic Hyperplasia The Journal of Urology. 226. DOI: 10.1097/00005392-199904010-00905 |
0.57 |
|
| 1999 |
Kyprianou N, Benning CM, Chon JK, Rowely DR. Doxazosin Regulates Growth Of Human Prostate Smooth Muscle And Prostate Cancer Cells By Inducing Apoptosis The Journal of Urology. 132. DOI: 10.1097/00005392-199904010-00532 |
0.623 |
|
| 1999 |
Guo Y, Kyprianou N. RESTORATION OF TGF-beta SIGNALING PATHWAY IN HUMAN PROSTATE CANCER CELLS SUPPRESSES TUMORIGENICITY VIA INDUCTION OF CASPASE-1-MEDIATED APOPTOSIS The Journal of Urology. 128. DOI: 10.1097/00005392-199904010-00513 |
0.587 |
|
| 1999 |
Kyprianou N. Induction of Prostate Apoptosis in Response to α1‐Adrenoceptor Antagonists: Therapeutic Significance in Benign Prostatic Hyperplasia and Prostate Cancer The Prostate Journal. 1: 73-81. DOI: 10.1046/J.1525-1411.1999.09918.X |
0.615 |
|
| 1998 |
Mackey TJ, Borkowski A, Amin P, Jacobs SC, Kyprianou N. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 52: 1085-90. PMID 9836559 DOI: 10.1016/S0090-4295(98)00360-4 |
0.637 |
|
| 1998 |
KYPRIANOU N, LITVAK JP, BORKOWSKI A, ALEXANDER R, JACOBS SC. INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA Journal of Urology. 159: 1810-1815. DOI: 10.1016/S0022-5347(01)63162-8 |
0.592 |
|
| 1997 |
Kyprianou N, Bains A, Rhee JG. Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. The Prostate. 32: 266-71. PMID 9288185 DOI: 10.1002/(Sici)1097-0045(19970901)32:4<266::Aid-Pros6>3.0.Co;2-H |
0.617 |
|
| 1997 |
Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. International Journal of Cancer. 71: 573-9. PMID 9178810 DOI: 10.1002/(Sici)1097-0215(19970516)71:4<573::Aid-Ijc11>3.0.Co;2-D |
0.491 |
|
| 1997 |
Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. International Journal of Cancer. 70: 341-8. PMID 9033638 DOI: 10.1002/(Sici)1097-0215(19970127)70:3<341::Aid-Ijc16>3.0.Co;2-I |
0.463 |
|
| 1996 |
Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. International Journal of Cancer. 69: 357-63. PMID 8900367 DOI: 10.1002/(Sici)1097-0215(19961021)69:5<357::Aid-Ijc1>3.0.Co;2-4 |
0.646 |
|
| 1996 |
Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Human Pathology. 27: 668-75. PMID 8698310 DOI: 10.1016/S0046-8177(96)90396-2 |
0.619 |
|
| 1996 |
King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of Apoptosis, Cell Proliferation and bcl-2 Expression in Transitional Cell Carcinoma of the Bladder: Association with Tumor Progression Journal of Urology. 155: 316-320. DOI: 10.1016/S0022-5347(01)66652-7 |
0.456 |
|
| 1995 |
Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World Journal of Urology. 12: 299-303. PMID 7881465 DOI: 10.1007/BF00184107 |
0.595 |
|
| 1995 |
Benoit RM, Eiseman J, Jacobs SC, Kyprianou N. Reversion of human prostate tumorigenic growth by azatyrosine. Urology. 46: 370-7. PMID 7660512 DOI: 10.1016/S0090-4295(99)80222-2 |
0.572 |
|
| 1995 |
Burno DK, Kyprianou N, Sartor WM, Fabian DF, Turner J, Vu T, Patel A, Trimbach C, Lefor AT. Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery. 118: 237-43; discussion 2. PMID 7638739 DOI: 10.1016/S0039-6060(05)80329-0 |
0.324 |
|
| 1995 |
Sartor WM, Kyprianou N, Fabian DF, Lefor AT. Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumor growth rate. The Journal of Surgical Research. 59: 66-74. PMID 7630139 DOI: 10.1006/Jsre.1995.1133 |
0.337 |
|
| 1994 |
Burney TL, Rockove S, Eiseman JL, Jacobs SC, Kyprianou N. Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. The Prostate. 25: 177-88. PMID 8084835 DOI: 10.1002/Pros.2990250403 |
0.548 |
|
| 1994 |
Kyprianou N, Bains AK, Jacobs SC. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. The Prostate. 25: 66-75. PMID 8036180 DOI: 10.1002/pros.2990250203 |
0.547 |
|
| 1994 |
Tu H, Jacobs SC, Mergner WJ, Kyprianou N. Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology. 44: 726-31. PMID 7974946 DOI: 10.1016/S0090-4295(94)80215-7 |
0.423 |
|
| 1993 |
Sklar GN, Eddy HA, Jacobs SC, Kyprianou N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. The Journal of Urology. 150: 1526-32. PMID 8411447 DOI: 10.1016/S0022-5347(17)35835-4 |
0.611 |
|
| 1992 |
Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. Journal of Andrology. 13: 457-464. DOI: 10.1002/J.1939-4640.1992.Tb00337.X |
0.578 |
|
| 1991 |
Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology. 127: 2963-8. PMID 2249636 DOI: 10.1210/Endo-127-6-2963 |
0.443 |
|
| 1991 |
Bartek J, Bartkova J, Kyprianou N, Lalani EN, Staskova Z, Shearer M, Chang S, Taylor-Papadimitriou J. Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proceedings of the National Academy of Sciences of the United States of America. 88: 3520-4. PMID 1708884 DOI: 10.1073/Pnas.88.9.3520 |
0.353 |
|
| 1990 |
Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Molecular Endocrinology (Baltimore, Md.). 3: 1515-22. PMID 2608047 DOI: 10.1210/Mend-3-10-1515 |
0.412 |
|
| 1990 |
Isaacs JT, Kyprianou N. Biological basis for chemohormonal therapy for prostatic cancer. Cancer Treatment and Research. 46: 177-93. PMID 2577189 DOI: 10.1007/978-1-4613-1595-7_10 |
0.491 |
|
| 1990 |
Kyprianou N, Isaacs JT. "Thymineless" death in androgen-independent prostatic cancer cells. Biochemical and Biophysical Research Communications. 165: 73-81. PMID 2531584 DOI: 10.1016/0006-291X(89)91035-8 |
0.48 |
|
| 1989 |
English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate. 15: 233-50. PMID 2555799 DOI: 10.1002/Pros.2990150304 |
0.349 |
|
| 1988 |
Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate. 13: 103-17. PMID 2845374 DOI: 10.1002/Pros.2990130203 |
0.416 |
|
| 1988 |
Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 122: 552-62. PMID 2828003 DOI: 10.1210/Endo-122-2-552 |
0.39 |
|
| 1987 |
Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. The Prostate. 11: 41-50. PMID 3658827 DOI: 10.1002/Pros.2990110106 |
0.476 |
|
| 1987 |
Kyprianou N, Isaacs JT. Biological significance of measurable androgen levels in the rat ventral prostate following castration. The Prostate. 10: 313-24. PMID 3601809 DOI: 10.1002/Pros.2990100405 |
0.345 |
|
| 1987 |
Isaacs JT, Kyprianou N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urological Research. 15: 133-8. PMID 3307086 DOI: 10.1007/Bf00254424 |
0.561 |
|
| 1987 |
Kyprianou N, Gingell JC, Davies P. Intranuclear distribution of androgen receptors in human prostate carcinoma. The Journal of Endocrinology. 112: 161-9. PMID 2434593 DOI: 10.1677/joe.0.1120161 |
0.397 |
|
| 1987 |
Kyprianou N, Isaacs JT. Biological Significance of Measurable Dihydrotestosterone (DHT) Levels in the Prostate Following Castration Journal of Urology. 137. DOI: 10.1016/S0022-5347(17)75248-2 |
0.509 |
|
| 1986 |
Kyprianou N, Davies P. Association states of androgen receptors in nuclei of human benign hypertrophic prostate. The Prostate. 8: 363-80. PMID 2423996 DOI: 10.1002/pros.2990080408 |
0.316 |
|
| 1986 |
Kyprianou N, Williams H, Peeling WB, Davies P, Griffiths K. Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. British Journal of Urology. 58: 41-4. PMID 2418903 DOI: 10.1111/j.1464-410X.1986.tb05425.x |
0.336 |
|
| Show low-probability matches. |